Second or 3rd line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Updated results of the IFCT-1501 MAPS2 randomized phase 2 trial
2017 ◽
Vol 28
◽
pp. v648
◽
G. Zalcman
◽
J. Mazieres
◽
L. Greillier
◽
S. Lantuejoul
◽
P. Dô
◽
...
2021 ◽
Vol 22
(2)
◽
pp. 190-197
B C John Cho
◽
Laura Donahoe
◽
Penelope A Bradbury
◽
Natasha Leighl
◽
Shaf Keshavjee
◽
...
2005 ◽
Vol 23
(16_suppl)
◽
pp. 7179-7179
◽
L. M. Krug
◽
H. I. Pass
◽
V. W. Rusch
◽
D. J. Sugarbaker
◽
K. E. Rosenweig
◽
...
2020 ◽
Vol 21
(9)
◽
pp. 1213-1223
◽
Anna K Nowak
◽
W Joost Lesterhuis
◽
Peey-Sei Kok
◽
Chris Brown
◽
Brett GM Hughes
◽
...
2005 ◽
Vol 49
◽
pp. S222
◽
L. Krug
◽
H. Pass
◽
V. Rusch
◽
D. Sugarbaker
◽
K. Rosenzweig
◽
...
2019 ◽
Vol 20
(2)
◽
pp. 239-253
◽
Arnaud Scherpereel
◽
Julien Mazieres
◽
Laurent Greillier
◽
Sylvie Lantuejoul
◽
Pascal Dô
◽
...
Tariq Sethi
◽
Claire Rooney
2015 ◽
Vol 16
(16)
◽
pp. 1651-1658
◽
Rolf A Stahel
◽
Oliver Riesterer
◽
Alexandros Xyrafas
◽
Isabelle Opitz
◽
Michael Beyeler
◽
...
Carmine Pinto
◽
Paolo Andrea Zucali
◽
Maria Pagano
◽
Federica Grosso
◽
Giulia Pasello
◽
...
Close
Export Citation Format
Close
Share Document
Close